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We want to thank Naya and Anderson for their interest in the
reported outcome of the 6 month randomized, double blind,
double dummy, and placebo controlled study to compare
the efficacy of fixed dose regimens of salmeterol/fluticasone
combination (SFC) and formoterol/budesonide combination
(FBC).
While the original analysis plan defined analysis of
exacerbations assuming the Poisson distribution, this model
was shown to poorly fit the data when analysis was carried
out. As a result, the model was changed to assume a
negative binomial distribution which fitted the data much
better. However a time effect was noted (as seen in Fig. 2b
in the paper-plot of cumulative moderate/severe exacer-
bations over time) and it was felt that this effect needed to
be taken into account to ensure appropriate representation
of the data. The time effect was taken into account by
looking at all of the data (weeks 1–24) and adding specific
treatment by time interval interaction. There was a trend,
separating the SFC and FBC, which became significant in the
last 8 weeks. In the time from designing the study to
analysing results, it became apparent that moderate and
severe exacerbations were more clinically relevant than
mild exacerbations thus only moderate and severe exacer-
bations were investigated. Therefore, both the inclusion of
post hoc analysis and the conclusion that SFC is superior to
FBC in terms of moderate/severe exacerbations after a
period of 6 months are perfectly valid.nt matter & 2006 Elsevier Ltd. All rights reserved.
2006.10.024We chose to analyse the exacerbation rate during three
periods of 8 weeks treatment. This approach was previously
used in the GOAL study and seems a reasonable time period to
appreciate the medium term effect of treatments. We would
have liked to follow the groups for much longer to understand
the kinetics of exacerbation in relation to length of treatment
better, especially after the debate about the long acting beta
agonists has been revitalized in general terms.
The result of our post hoc analysis seems visually in
agreement with the data provided by Naya and Anderson in
their Fig. 1. However, the figure shows that regular
budesonide treatment has little if any influence on moder-
ate–severe exacerbations during the initial 6 months of
treatment. No data on how the combination FBC would
perform are given and it is of course not possible to
extrapolate from the effect of treatment with budesonide
to the effect from treatment with FBC. No data are given for
the procedures of analyses, the handling of drop outs, the
dose of budesonide, the compliance rate, and the inclusion
criteria to select the asthma population. The analysis cannot
be used as a comparison to the reported outcome in our study.
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